Dublin, Ireland

Time filter

Source Type

Dalbeth N.,University of Auckland | Milligan A.,Auckland District Health Board | Doyle A.J.,University of Auckland | Clark B.,Grafton Group | McQueen F.M.,University of Auckland
Arthritis Research and Therapy | Year: 2012

Introduction: Radiographic descriptions of gout have noted the tendency to hypertrophic bone changes. The aim of this study was to characterize the features of new bone formation (NBF) in gout, and to determine the relationship between NBF and other radiographic features of disease, particularly erosion and tophus.Methods: Paired plain radiographs (XR) and computed tomography (CT) scans of 798 individual hand and wrist joints from 20 patients with gout were analyzed. Following a structured review of a separate set of images, films were scored for the presence of the following features of NBF: spur, osteophyte, periosteal NBF, ankylosis and sclerosis. The relationship between NBF and other radiographic features was analyzed.Results: The most frequent forms of NBF were bone sclerosis and osteophyte. Spur and periosteal NBF were less common, and ankylosis was rare. On both XR and CT, joints with bone erosion were more likely to have NBF; for CT, if erosion was present, the odds ratios (OR) was 45.1 for spur, 3.3 for osteophyte, 16.6 for periosteal NBF, 26.6 for ankylosis and 32.3 for sclerosis, P for all < 0.01. Similarly, on CT, joints with intraosseous tophus were more likely to have NBF; if tophus was present, the OR was 48.4 for spur, 3.3 for osteophyte, 14.5 for periosteal NBF, 35.1 for ankylosis and 39.1 for sclerosis; P for all < 0.001.Conclusions: This detailed quantitative analysis has demonstrated that NBF occurs more frequently in joints affected by other features of gout. This work suggests a connection between bone loss, tophus, and formation of new bone during the process of joint remodelling in gout. © 2012 Dalbeth et al.; licensee BioMed Central Ltd.


Beliaev A.M.,Auckland City Hospital | Marshall R.J.,University of Auckland | Gordon M.,Grafton Group | Smith W.,Auckland City Hospital | Windsor J.A.,University of Auckland
Vox Sanguinis | Year: 2012

Background It is well known that blood transfusion is life-saving, but also that it carries a serious risk of transmitting viral infections. Introduction of new methods of testing for transmissible diseases, blood banking and dispatch regulations has considerably increased the cost of blood products. However, the clinical benefits and cost-effectiveness of allogeneic red-blood-cell (ARBC) transfusion remain assumed yet undetermined. We assessed the clinical benefits and cost-effectiveness of ARBC transfusion in severe anaemia. Methods This was a multicenter observational study comparing Jehovah's Witness (JW) patients with matched ARBC-transfused patients. Inclusion criteria were age ≥15years and severe anaemia (haemoglobin≤80g/l). Two JW patients with palliative care cancer and five JW patients with haemoglobin (Hb) concentration between 70·1 and 80g/l, mild symptoms of anaemia and Auckland Anaemia Mortality Risk Score of 0-3 were excluded. Results The entry criteria were met by 103 JW patients and the same number of patients treated with ARBC transfusion. ARBC transfusion reduced mortality by 94%, shock by 88%, gastrointestinal bleeding by 81%, infective complications by 81%, cardiac arrhythmia by 96%, angina by 86%, ischaemic myocardial injury by 81%, acute/acute on chronic renal failure by 66%, neurologic complications by 92%, delirium by 76%, depression by 91% and syncopal episodes by 95%. The incremental cost-effectiveness ratio of ARBC transfusion was 2011 US$22515 for death prevented. Conclusion ARBC transfusion in anaemic patients is clinically beneficial and cost-effective. © 2011 International Society of Blood Transfusion.


Bush J.A.,Grafton Group | McGrouther D.A.,University of Manchester | Young V.L.,BodyAesthetic Plastic Surgery and Skincare Center | Herndon D.N.,Shriners Burns Hospital | And 4 more authors.
Wound Repair and Regeneration | Year: 2011

Cutaneous scarring is an enormous medical problem with approximately 100 million patients acquiring scars each year. Scar prevention/reduction represents a significant, and largely unmet, clinical need. Research into the prophylactic modulation of scar outcome differs from research into other disease processes as the scar is not present at the start of the study; measurements of changes from baseline are impossible. Final scar morphology is influenced by many variables. A fundamental principle that should be observed in the prospective evaluation of scar prevention/reduction therapies is that, if left untreated, wounds in treatment and control groups should have healed with identical scars. Observation of this principle will allow the detection of true treatment effects. The many variables that influence scar morphology mean that the evaluation of potential pharmaceutical products for this indication favors the use of self-controlled designs in clinical trials. In this article, we review variables that affect scar morphology and recommend the self-controlled design for clinical trials aiming to establish proof of efficacy of scar prevention and reduction pharmaceuticals. With no pharmaceutical products currently licensed for this indication, this represents a new therapeutic area. The principles discussed will also have direct relevance to the wider fields of wound healing and regenerative medicine. © 2011 by the Wound Healing Society.


Cadirci M.,University of Manchester | Masala O.,Grafton Group | Pickett N.,Grafton Group | Binks D.,University of Manchester
Chemical Physics | Year: 2014

Colloidal CuInS2 quantum dots have been synthesised and characterised using absorption and photoluminescence spectroscopy, X-ray diffraction, inductive-coupled plasma atomic emission spectroscopy and thermogravimetric analysis. The ultrafast charge dynamics of these dots have been studied using transient absorption spectroscopy. Cooling of hot photo-generated carriers to the band edge occurred within 3-5 ps. Significant de-population of the band-edge was found to occur on a sub-nanosecond time-scale, and was attributed to hole-trapping. © 2014 Elsevier B.V. All rights reserved.


Bignell E.,Grafton Group | Cairns T.C.,TU Berlin | Throckmorton K.,University of Wisconsin - Madison | Nierman W.C.,J. Craig Venter Institute | Keller N.P.,University of Wisconsin - Madison
Philosophical Transactions of the Royal Society B: Biological Sciences | Year: 2016

Aspergillus fumigatus is a versatile fungus able to successfully exploit diverse environments from mammalian lungs to agricultural waste products. Among its many fitness attributes are dozens of genetic loci containing biosynthetic gene clusters (BGCs) producing bioactive small molecules (often referred to as secondary metabolites or natural products) that provide growth advantages to the fungus dependent on environment. Here we summarize the current knowledge of these BGCs—18 of which can be named to product—their expression profiles in vivo, and which BGCs may enhance virulence of this opportunistic human pathogen. Furthermore, we find extensive evidence for the presence of many of these BGCs, or similar BGCs, in distantly related genera including the emerging pathogen Pseudogymnoascus destructans, the causative agent of white-nose syndrome in bats, and suggest such BGCs may be predictive of pathogenic potential in other fungi. © 2016 The Author(s) Published by the Royal Society. All rights reserved.


PubMed | J. Craig Venter Institute, Grafton Group, University of Wisconsin - Madison and TU Berlin
Type: Journal Article | Journal: Philosophical transactions of the Royal Society of London. Series B, Biological sciences | Year: 2017

Aspergillus fumigatus is a versatile fungus able to successfully exploit diverse environments from mammalian lungs to agricultural waste products. Among its many fitness attributes are dozens of genetic loci containing biosynthetic gene clusters (BGCs) producing bioactive small molecules (often referred to as secondary metabolites or natural products) that provide growth advantages to the fungus dependent on environment. Here we summarize the current knowledge of these BGCs-18 of which can be named to product-their expression profiles in vivo, and which BGCs may enhance virulence of this opportunistic human pathogen. Furthermore, we find extensive evidence for the presence of many of these BGCs, or similar BGCs, in distantly related genera including the emerging pathogen Pseudogymnoascus destructans, the causative agent of white-nose syndrome in bats, and suggest such BGCs may be predictive of pathogenic potential in other fungi.This article is part of the themed issue Tackling emerging fungal threats to animal health, food security and ecosystem resilience.


Marjoribanks J.,Grafton Group | Proctor M.,Grafton Group | Farquhar C.,Grafton Group | Derks R.S.,Grafton Group
Cochrane database of systematic reviews (Online) | Year: 2010

BACKGROUND: Dysmenorrhoea is a common gynaecological problem consisting of painful cramps accompanying menstruation, which in the absence of any underlying abnormality is known as primary dysmenorrhoea. Research has shown that women with dysmenorrhoea have high levels of prostaglandins, hormones known to cause cramping abdominal pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are drugs which act by blocking prostaglandin production. OBJECTIVES: The purpose of this review is to compare nonsteroidal anti-inflammatory drugs used in the treatment of primary dysmenorrhoea versus placebo, versus paracetamol and versus each other, to evaluate their effectiveness and safety. SEARCH STRATEGY: We searched the following databases to May 2009: Cochrane Menstrual Disorders and Subfertility Group trials register, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and Web of Science. The National Research Register and the Clinical Trials Register were also searched. Abstracts of major scientific meetings and the reference lists of relevant articles were checked. SELECTION CRITERIA: All randomised controlled comparisons of NSAIDs versus placebo, other NSAIDs or paracetamol, when used to treat primary dysmenorrhoea. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trials for quality and extracted data, calculating odds ratios (ORs) for dichotomous outcomes and mean differences for continuous outcomes, with 95% confidence intervals (CIs). Inverse variance methods were used to combine data. MAIN RESULTS: Seventy-three randomised controlled trials were included. Among women with primary dysmenorrhoea, NSAIDs were significantly more effective for pain relief than placebo (OR 4.50, 95% CI: 3.85, 5.27). There was substantial heterogeneity for this finding (I(2) statistic =53%): exclusion of two outlying studies with no or negligible placebo effect reduced heterogeneity, resulting in an odds ratio of 4.14 (95% CI: 3.52, 4.86, I(2)=40%). NSAIDs were also significantly more effective for pain relief than paracetamol (OR 1.90, 95% CI:1.05 to 3.44). However, NSAIDS were associated with significantly more overall adverse effects than placebo (OR 1.37, 95% CI: 1.12 to 1.66). When NSAIDs were compared with each other there was little evidence of the superiority of any individual NSAID for either pain-relief or safety. However the available evidence had little power to detect such differences, as most individual comparisons were based on very few small trials. AUTHORS' CONCLUSIONS: NSAIDs are an effective treatment for dysmenorrhoea, though women using them need to be aware of the significant risk of adverse effects. There is insufficient evidence to determine which (if any) individual NSAID is the safest and most effective for the treatment of dysmenorrhoea.


BIRMINGHAM, England--(BUSINESS WIRE)--SCC* has announced its annual results for year ending March 2015, with Services revenue reaching £159m, up 22% and accounting for 24% of its total income. · Services revenue up 22% to £159m, now 24% of total revenue; · Gross Profit (GP) increase of 15% and margin rate up 3.7% in the year to 15.5%; · Share of GP from Services up 11% in the year to 55% of overall GP; · EBITDA up 25% on prior year to £19.4m; · PBT at £12.4m up 20% on prior year; · M2 print business contributes turnover of £27m and EBITDA of £1.6m. The transition has seen dramatic changes in the underlying business and hyper growth in Cloud Delivered Managed Services (CDMS – DCS & Connectivity), as SCC moves the business away from low margin product sales. Key to SCC EMEA’s strategy to reach £50m EBITDA by FY17 is its Services division, which saw an overall GP growth of 22% in FY15. This was supported by key new business wins with Kier Group, Samworth Brothers, Grafton Group, McDonald Hotels, United Utilities, Department for Work and Pensions, and WHSmith. SCC’s Professional Services business grew 11% versus last year, with Managed Services up 13% and growth from the new Flexible Resourcing service. As SCC continues to invest heavily in its Data Centre Services (DCS) – most recently taking a majority share in Fluidata, the Data Delivery Network – it enjoyed another year of accelerated growth, up 87% on FY14. DCS closes the year on £26m, with an Annualised Run Rate (ARR) of £34m. March 2015 alone saw Monthly Recurring Revenue (MRR) increase 100% compared to last year. As SCC’s Cloud platforms enter maturity, DCS GP closed the year at 44% from 25%, with ARR closing on £29.4m, 96% ahead of the previous year. Monthly DCS EBITDA closes 220% ahead of FY14, at an annualised EBITDA of £12m (pre-central costs). Following SCC’s acquisition of SSE’s Tier 3+ Data Centre in Fareham and our recent 2nd phase 360 rack Birmingham investment, our total rack capacity is over 1,800 and 14Mv of power, the business closes the year on 67% occupancy and annual rack growth of 145%. Looking ahead to FY16 for the combined UK business, turnover for Services business is expected to top £200m with Cloud Services set to close next March on £55m and an ARR of £70m. EBITDA is estimated to grow 30% to £25m, with stable Product revenues of £500m and overall revenues of £700m. SCC Chief Executive James Rigby said: “The business is firmly on track to achieve its 3-year target of £50m EBITDA. We now have a sizeable Services business to further our growth and margins through recurring revenues. “Cloud Delivered Managed Services is the way forward for SCC. We have already started our next phase with a £10m investment in our own Data Centres, building additional data halls at Birmingham and Fareham facilities to increase capacity to 3,000 racks in FY16 to cater for CDMS growth of up to 60%. “SCC has always been a company with vision and an ability to deliver. We have an exciting year ahead as we grow our Services business organically and through further investments.” In Europe, SCC France recorded its best year of EBITDA for a second consecutive year, up 5.4% to £15.7m. Overall revenue in France closed on £812m a 3% improvement in constant currency terms. SCC Spain increased its revenue by £8m to £48m versus FY14 – a constant currency increase of 30%, with EBITDA of £0.6m, up 123%, as it continues its own transition to a services led business. And SCC Romania saw revenues of £9.2m, while the business delivered a 103% increase of EBITDA to £1.2m. During the year, headcount grew to 711 people at the facilities in Iasi and Bacau. During FY16, it is expected to grow to more than 1,200 people. SCC EMEA closed the year on £1.55bn revenue and EBITDA of £35.2m; an increase of 10% over the prior year. People do business, we make it work. We enable people to do business by planning, supplying, integrating and managing their IT. We make IT work through partnership, knowledge and passion: trusted to run IT infrastructure and services for leading business across Europe for 40 years. This information was brought to you by Cision http://news.cision.com


BIRMINGHAM, England--(BUSINESS WIRE)--SCC* has announced its annual results for year ending March 2015, with Services revenue reaching £159m, up 22% and accounting for 24% of its total income. · Services revenue up 22% to £159m, now 24% of total revenue; · Gross Profit (GP) increase of 15% and margin rate up 3.7% in the year to 15.5%; · Share of GP from Services up 11% in the year to 55% of overall GP; · EBITDA up 25% on prior year to £19.4m; · PBT at £12.4m up 20% on prior year; · M2 print business contributes turnover of £27m and EBITDA of £1.6m. The transition has seen dramatic changes in the underlying business and hyper growth in Cloud Delivered Managed Services (CDMS – DCS & Connectivity), as SCC moves the business away from low margin product sales. Key to SCC EMEA’s strategy to reach £50m EBITDA by FY17 is its Services division, which saw an overall GP growth of 22% in FY15. This was supported by key new business wins with Kier Group, Samworth Brothers, Grafton Group, McDonald Hotels, United Utilities, Department for Work and Pensions, and WHSmith. SCC’s Professional Services business grew 11% versus last year, with Managed Services up 13% and growth from the new Flexible Resourcing service. As SCC continues to invest heavily in its Data Centre Services (DCS) – most recently taking a majority share in Fluidata, the Data Delivery Network – it enjoyed another year of accelerated growth, up 87% on FY14. DCS closes the year on £26m, with an Annualised Run Rate (ARR) of £34m. March 2015 alone saw Monthly Recurring Revenue (MRR) increase 100% compared to last year. As SCC’s Cloud platforms enter maturity, DCS GP closed the year at 44% from 25%, with ARR closing on £29.4m, 96% ahead of the previous year. Monthly DCS EBITDA closes 220% ahead of FY14, at an annualised EBITDA of £12m (pre-central costs). Following SCC’s acquisition of SSE’s Tier 3+ Data Centre in Fareham and our recent 2nd phase 360 rack Birmingham investment, our total rack capacity is over 1,800 and 14Mv of power, the business closes the year on 67% occupancy and annual rack growth of 145%. Looking ahead to FY16 for the combined UK business, turnover for Services business is expected to top £200m with Cloud Services set to close next March on £55m and an ARR of £70m. EBITDA is estimated to grow 30% to £25m, with stable Product revenues of £500m and overall revenues of £700m. SCC Chief Executive James Rigby said: “The business is firmly on track to achieve its 3-year target of £50m EBITDA. We now have a sizeable Services business to further our growth and margins through recurring revenues. “Cloud Delivered Managed Services is the way forward for SCC. We have already started our next phase with a £10m investment in our own Data Centres, building additional data halls at Birmingham and Fareham facilities to increase capacity to 3,000 racks in FY16 to cater for CDMS growth of up to 60%. “SCC has always been a company with vision and an ability to deliver. We have an exciting year ahead as we grow our Services business organically and through further investments.” In Europe, SCC France recorded its best year of EBITDA for a second consecutive year, up 5.4% to £15.7m. Overall revenue in France closed on £812m a 3% improvement in constant currency terms. SCC Spain increased its revenue by £8m to £48m versus FY14 – a constant currency increase of 30%, with EBITDA of £0.6m, up 123%, as it continues its own transition to a services led business. And SCC Romania saw revenues of £9.2m, while the business delivered a 103% increase of EBITDA to £1.2m. During the year, headcount grew to 711 people at the facilities in Iasi and Bacau. During FY16, it is expected to grow to more than 1,200 people. SCC EMEA closed the year on £1.55bn revenue and EBITDA of £35.2m; an increase of 10% over the prior year. People do business, we make it work. We enable people to do business by planning, supplying, integrating and managing their IT. We make IT work through partnership, knowledge and passion: trusted to run IT infrastructure and services for leading business across Europe for 40 years. This information was brought to you by Cision http://news.cision.com

Loading Grafton Group collaborators
Loading Grafton Group collaborators